Amandine Durand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amandine Durand has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Isabelle André-Schmutz
Paris Cité University, Imagine Institute, Paris, France
5 shared publications - Geneviève de Saint Basile
Molecular basis of altered immune homeostasis laboratory Université de Paris Imagine Institute INSERM UMR 1163 75015 Paris France
4 shared publications - Tayebeh-Shabi Soheili
Human Lymphohaematopoiesis Laboratory, INSERM U1163, Paris, France
4 shared publications - Chantal Lagresle-Peyrou
Paris Cité University, Imagine Institute, Paris, France
3 shared publications Julie Rivière
Human Lymphohaematopoiesis Laboratory, INSERM U1163, Paris, France
3 shared publications- Marina Cavazzana
Imagine Institute, Paris, France
3 shared publications
Latest Publications
- Open Access
- 28 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (9) , eaax7781
Skin-specific antibodies neutralizing mycolactone toxin during the spontaneous healing of Mycobacterium ulcerans infection
Buruli ulcer, a neglected tropical infectious disease, is caused by Mycobacterium ulcerans. Without treatment, its lesions can progress to chronic skin ulcers, but spontaneous healing is observed in 5% of cases, suggesting the possible establishment of a host strategy counteracting the effects of M. ulcerans. We reveal here a skin-specific local humoral signature of the spontaneous healing process, associated with a rise in antibody-producing cells and specific recognition of mycolactone by the mouse IgG2a immunoglobulin subclass. We demonstrate the production of skin-specific antibodies neutralizing the immunomodulatory activity of the mycolactone toxin, and confirm the role of human host machinery in triggering effective local immune responses by the detection of anti-mycolactone antibodies in patients with Buruli ulcer. Our findings pave the way for substantial advances in both the diagnosis and treatment of Buruli ulcer in accordance with the most recent challenges issued by the World Health Organization.
- 28 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (9) , eaax7781
Open AccessSkin-specific antibodies neutralizing mycolactone toxin during the spontaneous healing of Mycobacterium ulcerans infection
Buruli ulcer, a neglected tropical infectious disease, is caused by Mycobacterium ulcerans. Without treatment, its lesions can progress to chronic skin ulcers, but spontaneous healing is observed in 5% of cases, suggesting the possible establishment of a host strategy counteracting the effects of M. ulcerans. We reveal here a skin-specific local humoral signature of the spontaneous healing process, associated with a rise in antibody-producing cells and specific recognition of mycolactone by the mouse IgG2a immunoglobulin subclass. We demonstrate the production of skin-specific antibodies neutralizing the immunomodulatory activity of the mycolactone toxin, and confirm the role of human host machinery in triggering effective local immune responses by the detection of anti-mycolactone antibodies in patients with Buruli ulcer. Our findings pave the way for substantial advances in both the diagnosis and treatment of Buruli ulcer in accordance with the most recent challenges issued by the World Health Organization.
- 21 December 2017
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (27) , 2781-2789
Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency
Patients with mutations in the UNC13D gene (coding for Munc13-4 protein) suffer from familial hemophagocytic lymphohistiocytosis type 3 (FHL3), a life-threatening immune and hyperinflammatory disorder. The only curative treatment is allogeneic hematopoietic stem cell (HSC) transplantation, although the posttreatment survival rate is not satisfactory. Here, we demonstrate the curative potential of UNC13D gene correction of HSCs in a murine model of FHL3. We generated a self-inactivating lentiviral vector, used it to complement HSCs from Unc13d-deficient (Jinx) mice, and transplanted the cells back into the irradiated Jinx recipients. This procedure led to complete reconstitution of the immune system (ie, to wild-type levels). The recipients were then challenged with lymphocytic choriomeningitis virus to induce hemophagocytic lymphohistiocytosis (HLH)–like manifestations. All the clinical and biological signs of HLH were significantly reduced in mice having undergone HSC UNC13D gene correction than in nontreated animals. This beneficial effect was evidenced by the correction of blood cytopenia, body weight gain, normalization of the body temperature, decreased serum interferon-γ level, recovery of liver damage, and decreased viral load. These improvements can be explained by the restoration of the CD8+ T lymphocytes’ cytotoxic function (as demonstrated here in an in vitro degranulation assay). Overall, our results demonstrate the efficacy of HSC gene therapy in an FHL-like setting of immune dysregulation. Key Points UNC13D gene transfer into HSCs corrects all clinical and biological signs of HLH in a mouse model. Munc13-4 is expressed in mature CD8+ T cells allowing the correction of cytotoxic activity and consequently efficient viral restriction. Visual Abstract
- 21 December 2017
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (27) , 2781-2789
Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency
Patients with mutations in the UNC13D gene (coding for Munc13-4 protein) suffer from familial hemophagocytic lymphohistiocytosis type 3 (FHL3), a life-threatening immune and hyperinflammatory disorder. The only curative treatment is allogeneic hematopoietic stem cell (HSC) transplantation, although the posttreatment survival rate is not satisfactory. Here, we demonstrate the curative potential of UNC13D gene correction of HSCs in a murine model of FHL3. We generated a self-inactivating lentiviral vector, used it to complement HSCs from Unc13d-deficient (Jinx) mice, and transplanted the cells back into the irradiated Jinx recipients. This procedure led to complete reconstitution of the immune system (ie, to wild-type levels). The recipients were then challenged with lymphocytic choriomeningitis virus to induce hemophagocytic lymphohistiocytosis (HLH)–like manifestations. All the clinical and biological signs of HLH were significantly reduced in mice having undergone HSC UNC13D gene correction than in nontreated animals. This beneficial effect was evidenced by the correction of blood cytopenia, body weight gain, normalization of the body temperature, decreased serum interferon-γ level, recovery of liver damage, and decreased viral load. These improvements can be explained by the restoration of the CD8+ T lymphocytes’ cytotoxic function (as demonstrated here in an in vitro degranulation assay). Overall, our results demonstrate the efficacy of HSC gene therapy in an FHL-like setting of immune dysregulation. Key Points UNC13D gene transfer into HSCs corrects all clinical and biological signs of HLH in a mouse model. Munc13-4 is expressed in mature CD8+ T cells allowing the correction of cytotoxic activity and consequently efficient viral restriction. Visual Abstract
- Open Access
- 15 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (24) , 2859-2862
Gene-corrected human Munc13-4–deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice
- 15 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (24) , 2859-2862
Open AccessGene-corrected human Munc13-4–deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice
- 1 December 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (6) , 1681-1689.e8
X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene
- 1 December 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (6) , 1681-1689.e8
X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S300
759. Reduction of HLH-like Manifestations in Murine Model of Munc13-4 Deficiency Following Lentiviral Gene Transfer into Hematopoietic Stem and Progenitor Cells
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S300
Open Access759. Reduction of HLH-like Manifestations in Murine Model of Munc13-4 Deficiency Following Lentiviral Gene Transfer into Hematopoietic Stem and Progenitor Cells
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S270
682. Correction of CTLs Cytotoxic Function Defect by SIN-lentiviral Mediated Expression of Munc13-4 in Type 3 Familial Hemophagocytic Lymphohistiocytosis
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S270
Open Access682. Correction of CTLs Cytotoxic Function Defect by SIN-lentiviral Mediated Expression of Munc13-4 in Type 3 Familial Hemophagocytic Lymphohistiocytosis
- Open Access
- 6 November 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (19) , 3023-3025
Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL
International audienceno abstrac
- 6 November 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (19) , 3023-3025
Open AccessCryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL
International audienceno abstrac